Navigating through blood vessels during interventional radiology procedures is no easy task. But Toshiba American Medical Systems, Inc. hopes to make it easier with its Volume Navigation 3-D roadmapping software for the InfinixTM-i vascular X-ray product line. The system was on display this week at the Society of Interventional Radiology’s (SIR) annual meeting in Chicago.
Navigating through blood vessels during interventional radiology procedures is no easy task. But Toshiba American Medical Systems, Inc. hopes to make it easier with its Volume Navigation 3-D roadmapping software for the InfinixTM-i vascular X-ray product line. The system was on display this week at the Society of Interventional Radiology’s (SIR) annual meeting in Chicago.
The system uses a real-time road map, and can show the deployment of coils during a cerebral aneurysm procedure. The software matches up the system component’s movements with a fused 3-D and fluoroscopic display. Users can choose 2-D or 3-D displays (or each on a different monitor), and can they can control or fine tune the images with manual controls. The system is good for imaging intricate vascular areas, such as the brain, uterus and abdominal region.
“Volume Navigation provides physicians greater confidence when deciphering and navigating complex vascular structures, enabling them to perform complicated interventions more quickly and accurately,” Doug Ryan, vice president of marketing and strategic development of Toshiba, said in a statement.
The Volume Navigation system received 510(k) clearance last September and can be added on to all Toshiba Infinix-i vascular X-ray systems. Currently the system is installed at Western Medical Center in Santa Ana, Calif.
Toshiba’s product is similar to others on the market. GE Healthcare introduced Innova Vision and Innova TrackVision, for use on its Innova 4100 IQ X-ray imaging system in 2009. It also uses fluoroscopy and provides 3-D renderings, roadmapping, navigation and image-guided intervention. The system allows users to overlay a 3-D rotational X-ray, MR, or CT image with 2-D fluoroscopic image to help users advance guide wires, coils, catheters, and other devices with real-time images. They also offer a Subtracted 3-D program to visualize the vessels, removing unwanted structures to more clearly view the anatomy of interest, according to Paul Brooks, commercial marketing manager for interventional radiology at GE Healthcare.
Other companies offering a 3-D roadmapping system include Philips, with its Dynamic 3-D Roadmap.
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
2 Commerce Drive
Cranbury, NJ 08512